Monte Rosa Therapeutics Net Profit Margin Growth & History (GLUE)
Monte Rosa Therapeutics's net profit margin was −31.23% for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −31.23% | +64.90 pp |
| 2024 | 2024-12-31 | −96.14% | — |
Monte Rosa Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −483.91% | −430.90 pp |
| Q1 2026 | 2026-03-31 | −1,057.08% | −1112.28 pp |
| Q4 2025 | 2025-12-31 | −1,658.94% | −1681.09 pp |
| Q3 2025 | 2025-09-30 | −212.10% | +46.79 pp |
| Q2 2025 | 2025-06-30 | −53.01% | +592.57 pp |
| Q1 2025 | 2025-03-31 | 55.20% | +3059.72 pp |
| Q4 2024 | 2024-12-31 | 22.16% | — |
| Q3 2024 | 2024-09-30 | −258.89% | — |
| Q2 2024 | 2024-06-30 | −645.58% | — |
| Q1 2024 | 2024-03-31 | −3,004.51% | — |
Monte Rosa Therapeutics net profit margin trends
Between the periods ended 2024-12-31 and 2025-12-31, Monte Rosa Therapeutics's net profit margin increased from −96.14% to −31.23%, a change of +64.90 percentage points. The latest reported quarter, Q2 2026, shows −483.91%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗